Efficacy and Safety of Cabozantinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study

Abstract

A multicenter retrospective study was conducted to evaluate the efficacy and safety of cabozantinib in patients with advanced or metastatic renal cell carcinoma (mRCC). We enrolled 53 patients with mRCC who received cabozantinib at eight institutions in Japan. The primary endpoint was overall survival (OS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). In addition, we analyzed prognostic factors in patients with mRCC treated with cabozantinib. The median follow-up period was 8 months, and the median OS was 20.0 months. The ORR and DCR were 39.6% and 83.0%, respectively. The median PFS was 11.0 months. PFS was significantly shorter in patients previously treated with at least two tyrosine kinase inhibitors and in those with C-reactive protein (CRP) ≥ 1.27 mg/dL (p = 0.021 and p = 0.029, respectively). Adverse events of any grade and grades ≥3 occurred in 42 (79.2%) and 10 (18.9%) patients, respectively. Cabozantinib is a useful treatment option for patients with mRCC and may benefit from earlier use. In this study, CRP ≥ 1.27 mg/dL is a poor prognostic factor in patients treated with cabozantinib, and careful follow-up may be required in treating patients with high CRP.

Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study

“…The necessity for dose reduction, observed in 49% of our patients in this study, closely parallels findings from the METEOR and CABOSUN trials, where dose reductions were required in 62% and 46% of patients, respectively. In another real-world experience study conducted by Bodnar et al, the incidence of all AEs was reported at 100% [24], while a study conducted by Iinuma et al reported an incidence of 79% [25].…”

Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients—Real-World Experience in a Single-Center Retrospective Study and Narrative Review

“…The search yielded 222 papers, but only 51 of them were considered consistent with the topic of this paper were retrieved from PubMed. Then, we analyzed in detail and finally included information from 27 [ 15 , 18 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 ] publications that were considered useful for this manuscript, while the remaining references came from the personal knowledge of the authors [ 49 , 50 ]. In the end, we qualified 13 [ 15 , 26 , 27 , 28 , 29 , 31 , 33 , 34 , 35 , 42 , 44 , 51 , 52 ] works to formulate a table describing AEs; in the remaining 14 papers, information about AEs was insufficient.…”